DESCRIPTION

Gentamicin Sulfate Ophthalmic Solution is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use.

Each mL contains

Active: Gentamicin Sulfate (equivalent to 3 mg gentamicin).

Inactives: Dibasic Sodium Phosphate, Sodium Chloride, Monobasic Sodium Phosphate, Purified Water. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (6.5 - 7.5).

Preservative Added: Benzalkonium Chloride 0.01%.

Gentamicin is an aminoglycoside antibiotic obtained from cultures of *Micromonospora purpurea*. It is a mixture of the sulfate salts of Gentamicin C₁, C₂, C₁a and C₂a. All three components appear to have similar antimicrobial activity.

Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:

![Structural formula of Gentamicin](image)

CLINICAL PHARMACOLOGY

Microbiology

Gentamicin sulfate is active *in vitro* against many strains of the following microorganisms:

*Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes Escherichia coli; Haemophilus influenzae, Klebsiella pneumoniae, Neisseria*
INDICATIONS AND USAGE
Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli; Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS
Gentamicin sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS
NOT FOR INJECTION INTO THE EYE
Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS
General
Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients
To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility
There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy
Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

ADVERSE REACTIONS
Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.
The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

Gentamicin Sulfate Ophthalmic Solution, USP 0.3% is supplied in a plastic bottle with a controlled drop tip and a white polypropylene cap in the following sizes:

NDC 24208-580-60 - 5 mL
NDC 24208-580-64 - 15 mL

NOT FOR INJECTION INTO THE EYE
FOR OPHTHALMIC USE ONLY
DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

Revised: August 2016

Bausch + Lomb, a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
©Bausch & Lomb Incorporated

9116003 (Folded)
9116103 (Flat)

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
Each ml contains:
Active: Gentamicin Sulfate, (equivalent to 3 mg Gentamicin);
Inactives: Dibasic Sodium Phosphate, Sodium Chloride,
Monobasic Sodium Phosphate, Purified Water, Hydrochloric Acid
and/or Sodium Hydroxide may be added to adjust pH (6.5-7.5).
Preservative Added:
Benzalkonium Chloride 0.01%.

Usual Dosage:
Instill 1 or 2 drops into the affected eye(s) every 4 hours. See package insert.

NOT FOR INJECTION
INTO THE EYE
KEEP OUT OF REACH
OF CHILDREN.

Storage:
Store between 2°-25°C
(36°-77°F).
Avoid exposure to excessive heat.

DO NOT USE IF
IMPRINTED NECK BAND
IS NOT INTACT.

Bausch + Lomb, a division of Valeant Pharmaceuticals
North America LLC
Bridgewater, NJ 08807 USA
Product of Stephens Republic
©Bausch & Lomb Incorporated

NDC 24208-580-64
Gentamicin Sulfate
Ophthalmic Solution, USP
0.3%
(Sterile)

FOR OPHTHALMIC USE ONLY
GENTAMICIN SULFATE
gentamicin sulfate solution/ drops

Product Information

Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: OPHTHALMIC

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENTAMICIN SULFATE (UNII: 8X7386QRLV) (GENTAMICIN - UNII:T6Z9V481K9)</td>
<td>GENTAMICIN</td>
<td>3 mg in 1 mL</td>
</tr>
</tbody>
</table>

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)</td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE (UNII: 451W47IQ8X)</td>
<td></td>
</tr>
<tr>
<td>SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)</td>
<td></td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>HYDROCHLORIC ACID (UNII: QTT17582CB)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)</td>
<td></td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:24208-580-60</td>
<td>1 in 1 CARTON</td>
<td>05/11/1994</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:24208-580-64</td>
<td>5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:24208-580-64</td>
<td>1 in 1 CARTON</td>
<td>05/11/1994</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:24208-580-64</td>
<td>15 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA064048</td>
<td>05/11/1994</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Bausch & Lomb Incorporated (196603781)
### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bausch &amp; Lomb Incorporated</td>
<td>079587625</td>
<td>MANUFACTURE(24208-580)</td>
<td></td>
</tr>
</tbody>
</table>